Extended-Release PSE Points Acura At First Tamper-Resistant Formulation NDA
This article was originally published in The Tan Sheet
Executive Summary
Like extended-release PSE products already available OTC, a product with tamper-resistant formulation labeling must go through the NDA process. “The novelty of this to the FDA is what testing you do to demonstrate meth resistance … what labeling do you put on a product?” says Acura CEO Bob Jones.
You may also be interested in...
PSE Product Makes “Highly” Tamper-Resistant Claim With 100% Out Of Reach
Westport Pharmaceuticals says a claim of being “highly” resistant to PSE-extraction distinguishes Zephrex-D from the competition, but the distinction alone is not adding up to market-share gains in the nonprescription nasal decongestant space.
Jurors' Answers In FTC Complaint Against Prevagen Might Form A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.